Key Highlights

  • Barclays downgraded Cellectis (Nasdaq: CLLS) from Overweight to Underweight.
  • The price target was cut from $9.00 to $1.30.
  • The downgrade follows the company's decision to discontinue its clinical CAR-T portfolio and pivot to early-stage in vivo gene editing.

Barclays Cuts Rating and Price Target

Barclays downgraded Cellectis (Nasdaq: CLLS) from Overweight to Underweight on September 16, 2026, alongside a sharp reduction in its price target, from $9.00 to $1.30.

Strategic Pivot Prompts Reassessment

The downgrade follows Cellectis's (Nasdaq: CLLS) decision to discontinue its clinical CAR-T cell therapy portfolio and redirect resources toward early-stage in vivo gene editing. The shift represents a significant strategic reset for a company that had built its identity around allogeneic CAR-T development.

New Direction Carries Execution Risk

Barclays' reduced price target reflects the earlier-stage nature of in vivo gene editing relative to the clinical-stage CAR-T Assets Cellectis (Nasdaq: CLLS) is stepping away from, underscoring the execution risk embedded in the company's pivot.

What did Barclays change for Cellectis?

Its rating, from Overweight to Underweight, and its price target, from $9.00 to $1.30.

Why did Cellectis pivot its strategy?

The company discontinued its clinical CAR-T portfolio to focus on early-stage in vivo gene editing.

When was the downgrade issued?

September 16, 2026.